

FOR IMMEDIATE RELEASE

April 21, 2008

Listed Stock Name: Eisai Co., Ltd.
President & CEO: Haruo Naito
Headquarters: 4-6-10 Koishikawa Bunkyo-ku, Tokyo
Securities Code: 4523
Listed Locations: First Sections of the Tokyo Stock
Exchange & the Osaka Securities
Exchange
Inquiries: Akira Fujiyoshi
Vice President
Corporate Communications, Investor
Relations
Phone 81-3-3817-5120

ect of the

(Millions of yen)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A) (Announced on February 1, 2008)	739,000	117,000	121,000	78,500
Revised Forecast (B)	735,200	17,700	18,800	(17,500)
Changes in Amount (B-A)	(3,800)	(99,300)	(102,200)	(96,000)
Percentage of Change	(0.5)	(84.9)	(84.5)	(122.3)
(Reference) Business Results for the fiscal year ended March 31, 2007	674,111	105,263	110,462	70,614

(2) Non-Consolidated

(Millions of yen)

	Net Sales	Operating Income	Ordinary Income	Net Income
Previous Forecast (A)				

operation. The goodwill will be amortized over 20 years.

- R&D expense is expected to increase due to R&D activities expanding on a global basis. On the other hand, as a result of conversion to yen in operation results of the U.S. subsidiaries, sales and SG&A expense are expected to fall due to the decline in the value of the dollar in the fourth-quarter.
- Business performance of MGI PHARMA, INC. on a stand-alone basis for the two months following the acquisition is favorably reflected.
- Operating income and net income are expected to increase by 5% and 1%, respectively, from the previous year, when the impact of the application of business combination accounting of the acquisition of MGI PHARMA, INC. is set aside.

(Non-consolidated)

- R&D expense is expected to increase due to R&D activities expanding on a global basis.
- Loss on devaluation of investment securities will occur due to a weak stock market, in addition to loss from foreign exchange due to the decline in the value of the dollar in the fourth-quarter

3. Year-end Dividend Forecast

- Although business combination accounting applied to the acquisition of MGI PHARMA, INC. results in some impact on reported profit and loss of the company, cash-flow from operating activities is not affected. Therefore, the dividend policy will not be changed.
- Year-end dividend will be ¥65 per share, and remains the same as the previous forecast. As a result, annual dividend is expected to be ¥130 per share, an increase of ¥10 from the previous year.

4. Business forecast for the fiscal year ending March 31, 2009, (April 1, 2008 to March 31, 2009)

(Millions of yen)				
	Net Sales	Operating Income	Ordinary Income	Net Income
Annual				